

Engineering Global Pharmaceutical Manufacturing Systems in the New Environment



Rick Gunyon
Global Process Owner – Systems Engineering
Engineering Technology Center
Eli Lilly and Company



William D. Schindel
ICTT System Sciences



Typical Engineering Disciplines in Pharmaceutical Manufacturing



What was the “Old Environment” ???



**For decades pharmaceutical manufacturing relied on ‘quality by inspection’
Regulatory compliance took precedence over fundamental improvements**

- Use of “***Good Manufacturing Practices***” (GMPs)
- “Predicate Rules” (laws) and Guidance, e.g.
 - U.S. FDA
 - E.U. EMEA
 - Irish Medicines Board
 - and others....

For example, applicable U.S. FDA regulations include:

- 21CFR 210, 211
- 21CFR Part 11
- 21CFR 820

What was the “Old Environment” ???



Traditional Drivers:

- Few revisions to regulatory GMPs interpreted to suggest “status quo”
- Decades of regulatory inspections and enforcement actions provided ‘learning’
- Continued focus on patient safety relied on quality by inspection
- Essential need to remain “compliant with GMPs”
- Regulatory Expectation: “If it wasn’t documented, it didn’t happen.”

Outcomes:

- Conservative designs
- Status quo approaches
- **Excessive Verification, Validation and Documentation practices, e.g.**

1. **DOCUMENTING EVERYTHING**
2. **Reviewing, verifying and documenting that you documented everything**
3. **Documenting and explaining any documentation errors and/or omissions...**
4. **Then Reviewing and Approving these reviews and approvals...**

What was the “Old Environment” ???

**“Documentation-centric
Quality by Inspection?”**

***....perhaps there is a
better way....***



Pharmaceutical cGMPs

for the

21st Century

- A Risk-Based Approach

Final Report - Fall 2004

**Department of Health and Human Services
U.S. Food and Drug Administration**

September 2004

What's Driving Change?



“The Desired State” A Mutual Goal of Industry, Society, and Regulators:

“A maximally efficient, agile, flexible pharmaceutical manufacturing sector that reliably produces high-quality drug products without extensive regulatory oversight.”


Janet Woodcock, M.D.

Deputy Commissioner for Operations
Office of the Commissioner, FDA

October 5, 2005

**“Pharmaceutical Quality Systems”
“Sound process and product understanding”**

What's Driving Change?



Typical Pharma Manufacturing vs. World Class Operational Excellence (OPEX)

Key Performance Indicator	Typical Pharma Plant (2005)	A Winning Pharma Plant	World Class OPEX
Stock Turns (x / Year)	3 - 5	14	50
OTIF	60 – 80 %	94 %	96 %
RFT	85 – 95 %	96 %	99 %
Cpk	1 -2	2.5	3.2
OEE	30 %	74 %	92 %
Cycle Time (WIP Hrs.)	720	48	8

(Source: The Metamorphosis of Manufacturing © IBM Corporation, 2005)

OITF = (Order Filled) On Time In Full

RFT = Right First Time

Cpk = Process Capability Index

OEE = Overall Equipment Effectiveness

Emerging Trends:

Product and Process Quality Knowledge

Science-based and Risk-based Business Execution

Use of First Principles



Quality by Design


- Process Design via First Principles

Process Design

- Limited to the Experimental Design Space

Experimental Data

- Difficult to Assesses



Emerging Trend: Quality by Design (QbD)



OUTCOMES from QbD:

Robust process & product understanding
Manufacturing Systems:


“In-Control”
“Capable”
“Compliant”
“Continuously Improving”

IMPLICATIONS:


Systems - of - systems performance
Robust data & knowledge management
Across the full lifecycle

***Systems Engineering
Based on First Principles***

Business Process Workflows



SE Integration of Business Process Workflows




Systems Engineering as a Progressive Discipline




Summary of Approach

Systems Engineering includes scalable and progressive levels: SE, MBSE, PBSE, IBSE



Pharmaceutical Manufacturing ... *complex and interdependent Systems of systems*




Hierarchy	Types	Characteristics
Site		One Site = 1 – 5 Manufacturing Facilities
Facility		Typical Facility = 80 – 140 Subsystems
Area		Some are 'Area Systems'
Cell		Many are 'Cells'
Unit Operation		Cells contain 'Unit Operations'

Without SE, engineering of systems typically focused on the Facility, and the 80 – 140 subsystems within the Facility, regardless of their hierarchy.

SE recognizes the Facility is a type of System, and... the Facility and the 80 - 140 subsystems exist at various levels of hierarchical relationships.

SE introduces many important concepts, including Emergent Systemic Behavior, Information Modeling, Abstraction Hierarchy vs. Containment Hierarchy, Interoperability, Specialization, Configuration....

Pharmaceutical Manufacturing ... *complex and interdependent Systems of systems*




Hierarchy	Types	Characteristics
Site	1 – 5 Manufacturing Plants	
	United States of America # 1	
	United States of America # 2	
	Ireland	
	France	
	Italy	
Facility		
Area		
Cell		
Unit Operation		

API = Active Pharmaceutical Ingredient


Parenteral = administered other than via digestive canal, e.g. Injectable, Transdermal

Pharmaceutical Manufacturing ... complex and interdependent Systems of systems



Hierarchy	Types	Typical Facility Characteristics
Site		
Facility	Administration	Primarily Office Space
	Manufacturing	Product Networks by Type of Product / Process
	R&D / Pilot Plant	Pipeline R&D / Commercialization / Scale Up
	Distribution	Warehousing, Geographic Repackaging
	Utilities	Central Utility Generation & Distribution
	Multi-purpose	(Permutations and Combinations of Above)
Area		
Cell		
Unit Operation		
Component		

Pharmaceutical Manufacturing ... *complex and interdependent Systems of systems*




Hierarchy	Types	Typical Area Characteristics
Site		
Facility		
Area	General GMP Area	General manufacturing space – GMPs apply
	Aseptic Products	Free from contamination / cross contamination
	Dry Products	
	cGMP Laboratory	Analytical Lab Operations
	Administration	General office space
	Utility	Central Utility Generation & Distribution
Cell		

Pharmaceutical Manufacturing ... *complex and interdependent Systems of systems*



Hierarchy	Types	Typical Cell Characteristics
Site		
Facility		
Area		
Cell	Dispensing	Design & Control - Flow of People, Process, Material
	Coating	Process Safety Critical Operations
	Fill / Finish	Coating, Filling
	Bio Reactor	Large Molecule Replication – Living Cells
	Packaging	Primary and Secondary Packaging, Blister – Packing
	Labeling	Identification as required for Country of Distribution
Unit Operation		

Pharmaceutical Manufacturing ... *complex and interdependent Systems of systems*



Hierarchy	Types	Typical Unit Operation Processes
Site		
Facility		
Area		
Cell		
Unit Operation	Transverse Flow Filtration	Precise Filtration
	Lyophilization	Freeze Drying
	Decontamination (Autoclave)	Sterilization
	Roller Coating (Roll Coater)	Tablet Coating
	Inoculation Lab	Media Seeding


Pharmaceutical Manufacturing ... *complex and interdependent Systems of systems*



Hierarchy	Types	Typical Characteristics
Utilities	HVAC / Aseptic / Dry / non-GMP	HEPA / Diff. P / Laminar / Humidity
	Water Utilities	WFI, HWFI, HPW, PWEC, Potable
	Gas Utilities	Oxygen, Nitrogen, Breathing Air, Steam
	Data Infrastructure	Enterprise LAN, Automation, SCADA
	Electric	Dual – Feed, Emergency Generation
	Piped Liquid Distribution	Site / Local Distribution & Collection
	Aqueous Waste	Sanitary Sewer Load
	Solid Waste	Landfill Impact
	Other	Noise

Hierarchical View: Logical & Physical Systems

ANSI / ISA S-95



Physical Hierarchy

Site


Facility

Area

Cell

Unit Operation

Component



Typical Engineering Considerations Include:


Lifecycle States / Interactions

User Needs, Requirements
Design Development, Design Controls
Manufacture, Distribution and Storage
Customer Storage and Use Conditions
Device and Drug Product Interactions
Disposal

Key Considerations

Ease of use, injection force
Critical assembly characteristics
Stability, storage conditions
Ease of use, stability, storage
Drug delivery volume
Environmental impact

Pharmaceutical Product Manufacturing Process Overview




Typical API Manufacturing

Systems of Systems


Interactions of

- Systems
- Processes



API = Active Pharmaceutical Ingredient

Typical API Manufacturing



Basic SE Workflow


Implementing New Manufacturing Asset



1. Characterize Project
 2. Identify Functional Areas & Stakeholder Representatives
 3. Identify Stakeholder Needs & Resolve Inconsistencies
 4. Translate Needs into Requirements, Technical Specifications and Attributes
 5. Publish Accepted Technical Specifications as Basis of Acquisition
 6. Publish Accepted Requirements as Basis of Design
 7. Purchase / Build Asset
 8. Verification (Commissioning, etc.)
 9. Validation
 10. Release for use
- Basic SE does not rely on modeling of Features, Interactions, States, Roles...
 - Similar to Quality Function Deployment (QFD)



SE Information Model

Systematica™



MBSE


SE Feature Class Model, Pharma Manufacturing




MBSE

SE Feature Class Model, Pharma Manufacturing

Delivery Project Team




SE Feature Class Model, Pharma Manufacturing





MBSE


SE Interaction Class Model




MBSE SE Interaction Class Model



Pharma Facility Domain Model (Simplified)




Bioreactor Domain Model (Simplified)



Requirements Statements and Attributes

“During the specified phase, the Bioreactor System shall maintain temperature of the bioreactor vessel contents between [Min Temperature] and [Max Temperature].”


Recipe	Min Temperature	Max Temperature	Control Strategy	Acceptance Criteria
Product A	68 Degrees F	73 Degrees F	PID Strategy 3	Test Case 9
Product B	84 Degrees F	89 Degrees F	PID Strategy 3A	Test Case 23
Product C	69 Degrees F	73 Degrees F	PID Strategy 4	Test Case 25



Implementing and Sustaining SE via a Collaborative Environment

Web-based Collaborative Platform

Security & Privacy
Global Real Time Connectivity
Collaboration Portals
Documents
Applications
Forms
Blogs
Wiki



Opportunities (Challenges)



1. New Engineering Workflow

Transitioning a mature and highly-skilled engineering staff to the use of SE:

- Basic SE
- MBSE
- PBSE

2. Value Creation Outcomes

SE is well-positioned via SE First Principles, but we need to demonstrate:

- Hard Metrics - Quantified ROI
- Anecdotal Success Stories
- SE Workflow Utilization


Thank you so much !!

References



1. Alexander, C. et al 1977. *A pattern language: Towns, buildings, construction*. New York: Oxford U. Press.
2. ASTM 2009. ASTM Standards catalog web site: <http://www.astm.org/catalog.html>
3. Duda, R., et al. 2001. *Pattern classification*, (2nd ed.), New York: Wiley.
4. Eli Lilly and Company corporate web site: <http://www.lilly.com/>
5. EPA 2009. EPA Regulations catalog web site: <http://www.epa.gov/lawsregs/envtopics/index.html>
6. European Medicines Agency, EMEA web site: <http://www.emea.europa.eu/>
7. FDA 2009. U.S. Code of Federal Regulations 21CFR210 web site: <http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=210.1>
8. FDA 2004a. "Innovation and continuous improvement in pharmaceutical manufacturing — pharmaceutical cGMPs for the 21st century". Dept of Health and Human Services, U.S. Food and Drug Administration. September 2004. <http://www.fda.gov/cder/gmp/gmp2004/manufSCIWP.pdf>
9. FDA 2004b. "Final report on pharmaceutical cGMPs for the 21st century—a risk-based approach". Dept of Health and Human Services, U.S. Food and Drug Administration. September 2004. http://www.fda.gov/cder/gmp/gmp2004/GMP_finalreport2004.htm
10. FDA 2004c. "Q8 pharmaceutical development ICH draft: Step 2", November 18, 2004. <http://www.fda.gov/cder/guidance/6672.dft.htm>
11. Gamma, E., et al. 1995. *Design patterns: Elements of reusable object-oriented software*. Reading, MA: Addison-Wesley.
12. Haskins, C. 2005. "Application of patterns and pattern languages to systems engineering". Paper presented at the 15th annual international symposium of the international council on systems engineering, Rochester, NY.
13. Hopp, W., and Spearman, M. 2008. *Factory physics*, third edition. McGraw Hill. ISBN-10: 007123246X
14. IBM Corporation 2005. "The metamorphosis of manufacturing: From art to science". © IBM Global Services, Somers, NY.
15. ICH Quality Guidelines 2009, "ICHQ1" – "ICHQ10", International Conference on Harmonisation web site: <http://www.ich.org/cache/compo/276-254-1.html>

References



16. ICTT 2006. "Enhancing process engineering integration: An application of model-based systems engineering (MBSE)."
17. INCOSE 2009. INCOSE Model driven system design working group web site: <http://www.incose.org/practice/techactivities/wg/mdsd/> .
18. ISA 2009. ISA Standards publications web site: <http://www.isa.org/InTechTemplate.cfm?Section=Standards1&Template=/ContentManagement/AllContentList.cfm&ICID=%2778%2C89%27&PageName=Standards>
19. ISPE 2009. ISPE Guides and publications web site: http://www.ispe.org/cs/technical_documents_section/technical_documents_overview
20. Lilly 2009. Eli Lilly & Company web site: <http://www.lilly.com>
21. OSHA 2009. OSHA Standards catalog web site: <http://www.osha29cfr.com/>
22. Radspinner. 2004. "Implementation of PAT: An industry perspective." Sanofi-aventis. RPS/FDA/Meeting, London, December, 2004. <http://www.fda.gov/cder/OPS/Radspinner.pdf>
23. PDA 2001, "Real Compliance and How to Achieve It", Russell E. Madsen, PDA J Pharm Sci Technol. 2001 Mar-Apr;55(2):59-64
24. Scherzer. R. 2005. "Quality by design: A challenge to the pharma industry." CAMP, U.S. Food and Drug Administration Science Board, April 2002. <http://www.fda.gov/cder/OPS/Scherzer-Camp/index.htm>
25. Schindel, W. 2005a. Requirements statements are transfer functions: An insight from model-based systems engineering. Paper presented at the annual international symposium of the International Council on Systems Engineering, July, Rochester, NY.
26. Schindel, W. 2005b. Pattern-based systems engineering: An extension of model-based systems engineering. INCOSE TIES tutorial presented at 2005 INCOSE Symposium.
27. ____ ,2007. "Pattern-based systems engineering (PBSE): Outcomes and experiences." IEEE/INCOSE chapter joint meeting, Indianapolis.
28. Schindel, W. and Smith, V. 2002. Results of applying a families-of-systems approach to systems engineering of product line families. Technical Report 2002-01-3086. SAE International.